ZA

Zander Therapeutics, Inc

  • CIK: 0001718644
  • EIN: 47-4321638
  • Business address: 4700 SPRING ST, LA MESA, California, 91942-0274

Information

  • Mailing address
    4700 SPRING ST, LA MESA, Nevada, 91942-0274
  • Phone
    6192279192
  • State location
    California
  • State of incorporation
    Nevada
  • Fiscal year end
    June 30
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About Zander Therapeutics, Inc

Zander Therapeutics, Inc (CIK: 0001718644) is an American company incorporated in the state of California. Head office is located at 4700 SPRING ST, LA MESA, California, 91942-0274. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Zander Therapeutics, Inc is a public company and trade via Over-The-Counter (OTC).

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Zander Therapeutics, Inc

Filings Format Description Filed/Effective File/Film Number
8-K Document

Current report filing

Acc-no: 0001607062-20-000022 (34 Act) Size: 25 KB		 Jan-22-2020

333-220790

20538952
8-K Document

Current report filing

Acc-no: 0001607062-20-000007 (34 Act) Size: 14 KB		 Jan-07-2020

333-220790

20513678
8-K Document

Current report filing

Acc-no: 0001607062-19-000480 (34 Act) Size: 78 KB		 Dec-18-2019

333-220790

191291642
10-Q Document

Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001607062-19-000409 (34 Act) Size: 2214 KB		 Oct-25-2019

333-220790

191166826
8-K Document

Current report filing

Acc-no: 0001607062-19-000365 (34 Act) Size: 40 KB		 Sep-18-2019

333-220790

191099247
10-K Document

Annual report pursuant to section 13 and 15(d)

Acc-no: 0001607062-19-000354 (34 Act) Size: 3742 KB		 Aug-30-2019

333-220790

191069020
8-K Document

Current report filing

Acc-no: 0001607062-19-000297 (34 Act) Size: 14 KB		 Jul-02-2019

333-220790

19935896
UPLOAD Document Acc-no: 0000000000-19-010551 ( Act) Size: 44 KB Jul-02-2019

10-Q/A Document

Amendment to Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001607062-19-000295 (34 Act) Size: 2165 KB		 Jun-28-2019

333-220790

19928523
10-Q/A Document

Amendment to Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001607062-19-000292 (34 Act) Size: 2260 KB		 Jun-28-2019

333-220790

19928471
8-K Document

Current report filing

Acc-no: 0001607062-19-000272 (34 Act) Size: 25 KB		 Jun-18-2019

333-220790

19902731
CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001607062-19-000265 ( Act) Size: 11 KB		 Jun-12-2019

UPLOAD Document Acc-no: 0000000000-19-009715 ( Act) Size: 39 KB Jun-11-2019

CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001607062-19-000257 ( Act) Size: 7 KB		 Jun-10-2019

UPLOAD Document Acc-no: 0000000000-19-009412 ( Act) Size: 41 KB Jun-05-2019

8-K Document

Current report filing

Acc-no: 0001607062-19-000251 (34 Act) Size: 399 KB		 May-31-2019

333-220790

19870183
10-Q Document

Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001607062-19-000249 (34 Act) Size: 3023 KB		 May-31-2019

333-220790

19870162
NT 10-Q/A Document

Amendment to Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Acc-no: 0001607062-19-000241 (34 Act) Size: 26 KB		 May-24-2019

333-220790

19853119
NT 10-Q Document

Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Acc-no: 0001607062-19-000213 (34 Act) Size: 20 KB		 May-14-2019

333-220790

19822115
8-K Document

Current report filing

Acc-no: 0001607062-19-000181 (34 Act) Size: 53 KB		 Apr-26-2019

333-220790

19768860

Recent 20 filings. View all Zander Therapeutics, Inc filings

Reviews

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Frequently Asked Questions

Tags:

  • Zander Therapeutics, Inc overview
  • Zander Therapeutics, Inc job
  • Zander Therapeutics, Inc stock
  • Zander Therapeutics, Inc ownership
  • Zander Therapeutics, Inc CEO
  • Zander Therapeutics, Inc documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

Contineum Therapeutics, Inc.
Update: Mar 16, 2024
Cuprina Holdings (Cayman) LTD
Update: Mar 08, 2024
APRINOIA Therapeutics Inc.
Update: Jan 27, 2024
Zhengye Biotechnology Holding Ltd
Update: Jan 10, 2024
Alto Neuroscience, Inc.
Update: Nov 28, 2023
Mural Oncology plc
Update: Nov 02, 2023

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 3935 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 1392 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 1726 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 2692 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 1329 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 4752 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 2982 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 1227 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 2515 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by